Advanced Solid Tumors: BMS-986482 Study

We are investigating the safety and dosage of BMS-986482 alone or with other therapies for patients with advanced solid tumors. This study aims to understand how well it works in combination with existing treatments.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Bevacizumab
Bevacizumab is a substance that blocks formation of new blood vessels to treat certain cancers and eye conditions caused by abnormal vessel growth.
Nivolumab
Nivolumab is a substance that helps the immune system recognize and attack certain cancers.
Relatlimab
Relatlimab is an antibody that blocks the LAG-3 immune checkpoint to help the immune system attack certain cancers.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Bms986482
Nivolumab
Relatlimab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Universitair Ziekenhuis Gent
Drug Research Unit Ghent
Ledeberg, Belgium
Rigshospitalet
Department of Oncology
Copenhagen, Denmark
Centre Hospitalier Regional De Marseille
Centre d'Essais Précoces en Cancérologie de Marseille
Marseille, France

Sponsor: Bristol-Myers Squibb Services Unlimited Company
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.